Stay Ahead of the Game With Pfizer (PFE) Q2 Earnings: Wall Street's Insights on Key Metrics

Core Viewpoint - Analysts project that Pfizer will report quarterly earnings of $0.58 per share, reflecting a 3.3% decline year over year, with revenues expected to reach $13.78 billion, an increase of 3.7% from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised 0.2% lower over the last 30 days, indicating a collective reevaluation by analysts [2]. - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [3]. Revenue Projections - Analysts forecast 'Revenues- Oncology- Ibrance- Worldwide' to reach $1.05 billion, indicating a year-over-year decline of 6.9% [5]. - 'Revenues- Specialty Care- Xeljanz- Worldwide' is estimated at $219.35 million, reflecting a 27.6% decrease from the prior-year quarter [5]. - 'Revenues- Oncology- Xtandi alliance revenues- Worldwide' are expected to be $528.19 million, showing a year-over-year increase of 6.7% [6]. - 'Revenues- Specialty Care- Inflectra- Worldwide' is projected to reach $101.04 million, indicating a 4.2% increase year over year [6]. Regional Revenue Estimates - 'Revenues- Oncology- Ibrance- United States' is expected to be $702.67 million, reflecting a 5.2% decline year over year [7]. - 'Revenues- Specialty Care- Xeljanz- Total International' is estimated at $103.19 million, indicating a 15.4% decrease from the prior-year quarter [7]. - 'Revenues- Oncology- Ibrance- Total International' is projected to be $349.94 million, reflecting a 10.3% decline from the prior-year quarter [8]. - 'Revenues- Specialty Care- Xeljanz- United States' is expected to reach $116.16 million, indicating a significant year-over-year decline of 35.8% [8]. - 'Revenues- Oncology- Inlyta- Total International' is estimated at $89.23 million, reflecting an 11.7% decline from the prior-year quarter [9]. - 'Revenues- Oncology- Inlyta- United States' is projected to be $116.62 million, indicating a 22.8% decline year over year [9]. Primary Care Revenue Estimates - 'Revenue- Primary Care- Prevnar family- United States' is expected to be $826.39 million, reflecting a slight year-over-year decline of 0.7% [10]. - 'Revenue- Primary Care- Prevnar family- Total International' is projected to reach $536.11 million, indicating a 1.7% increase from the prior-year quarter [10]. Stock Performance - Pfizer shares have decreased by 6% in the past month, contrasting with the Zacks S&P 500 composite's increase of 2.7%, and the stock is expected to closely follow overall market performance in the near term [10].